2 results
Approved WMOCompleted
The primary objective of this study is to demonstrate that eritoran tetrasodium treatment of patients with severe sepsis results in a reduction in 28-day all-cause mortality.The secondary objectives are to confirm eritoran*s safety profile, and to…
Approved WMOCompleted
Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…